II.a

Pulmonary edema, noncardiogenic (NCPE)

(Fr: OAP non cardiogénique). A.k.a. permeability edema. Typically acute and florid. Less often subaute/benign. PE is common following drug overdose, especially when given I.V.. May accompany anaphylactic shock (PMID 29086053). May cause the ARDS picture. Drug-induced pulmonary edema cases generally have an acute or sudden onset, and are noncardiac (normal heart US and wedge pressure when measured) (NCPE). Transient fleeting pulmonary infiltrates were often reported as 'acute allergic pulmonary edema'. Hyperacute PE cases are sometimes called 'flash pulmonary edema' (see under IIi). Severe NCPE cases may exhibit the characteristic of ARDS (PMID 3532567, 15062601, 7555128, 1914570). The diagnosis of NCPE is raised when timing of the reaction is shortly (seconds to minutes) following administration of the causal drug or agent. NCPE is also a feature of anaphylaxis episodes (PMID 24376328). Patients with pulmonary hypertension are prone to the development of vasoldilator-induced NCPE (see under NO and other pulmonary vasodilator drugs). NCPE will generally relapse if the patient is reexposed to the drug. Note: overzealous administration of i.v. fluids or blood to a patient whose cardiocirculatory system cannot accomodate it may cause overload (hydrostatic) pulmonary edema (IIh) or TACO

Last update : 01/01/1970
 

Causative drugs

222

Immunoglobulins, intravenous (IVIG)

1

Immunotoxins

2

Inhalants (volatile substances)

1

Insulin

1

Interferon alpha/beta

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (May commpany ILDs) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
1

Interleukin 2 (IL2)

2

Irofulven

1

Isoxsuprine

2

Ketamine

1

Kratom (Mitragynine)

1

Levofolinate

1

Lidocaine (lignocaine, xylocaine)

1

Lipids (parenteral)

1

Liposuction

1

Loperamide

1

Losartan

1

Lymphocyte (donor) infusion

1

Magnesium sulfate

1

Mercury fumes/vapor

1

Metamizole

1

Metaraminol

1

Methadone

I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation) VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VI.g VI - Pulmonary vasculopathies
VI.g - Foreign body pulmonary vasculopathy (Excipient lung disease) IX.c IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.c - Chest wall muscle rigidity - Stiff/wooden chest IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis) IX.e IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.e - Disordered breathing pattern - Cheynes-Stokes respiration IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.p XII - Cardiovascular involvement / toxicity
XII.p - QTc prolongation XII.t XII - Cardiovascular involvement / toxicity
XII.t - Torsades de pointe XII.bo XII - Cardiovascular involvement / toxicity
XII.bo - Right ventricular dysfunction.failure
2

Methadone, inhaled

1

Methamphetamine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.ae VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ae - 'Meth mouth' IX.ae IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ae - Stroke X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.ba XII - Cardiovascular involvement / toxicity
XII.ba - Sudden cardiac death XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction
1

Methaqualone

1

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies